Second-line Treatments for Advanced Gastric Cancer: A Network Meta-Analysis of Overall Survival Using Parametric Modelling MethodsReportar como inadecuado

Second-line Treatments for Advanced Gastric Cancer: A Network Meta-Analysis of Overall Survival Using Parametric Modelling Methods - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Oncology and Therapy

, Volume 5, Issue 1, pp 53–67

First Online: 06 June 2017Received: 10 April 2017DOI: 10.1007-s40487-017-0048-0

Cite this article as: Harvey, R.C. Oncol Ther 2017 5: 53. doi:10.1007-s40487-017-0048-0


IntroductionAdvanced gastric cancer AGC is one of the most common forms of cancer and remains difficult to cure. There is currently no recommended therapy for second-line AGC in the UK despite the availability of various interventions. This paper aims to compare different interventions for treatment of second-line AGC using more complex methods to estimate relative efficacy, fitting various parametric models and to compare results to those published adopting conventional methods of synthesis.

MethodsSeven studies were identified in an existing literature review evaluating seven comparators, which formed a connected network of evidence. Citations were limited to randomised controlled trials in previously-treated AGC patients. Evidence quality was assessed using the Cochrane Collaboration’s tool. Studies were assessed for the availability of Kaplan–Meier curves for overall survival. Individual patient data IPD were recreated using digitisation software along with a published algorithm in R. The data were analysed using multi-dimensional network meta-analysis NMA methods. A series of parametric models were fitted to the pseudo-IPD. Both fixed and random-effects models were fitted to explore long-term survival prospects based on extrapolation methods and estimated mean survival.

ResultsRelative efficacy estimates were compared to those previously reported, which utilised conventional NMA methods. Results presented were consistent within findings from other publications and identified ramucirumab plus paclitaxel as the best treatment; however, all the treatments assessed were associated with poor survival prospects with mean survival estimates ranging from 5.0 to 12.7 months.

ConclusionWhilst the approach adopted in this paper does not adjust for differences in trial patient populations and is particularly data-intensive, use of such sophisticated methods of evidence synthesis may be more informative for subsequent cost-effectiveness modelling and may have greater impact when considering an indication where observed data is particularly immature or survival prospects are more positive, which may then lead to more informative decision-making for drug reimbursement.

KeywordsAdvanced gastric cancer Bayesian Evidence synthesis Network meta-analysis Parametric modelling Enhanced contentTo view enhanced content for this article go to

Electronic supplementary materialThe online version of this article doi:10.1007-s40487-017-0048-0 contains supplementary material, which is available to authorized users.

Autor: Rebecca C. Harvey


Documentos relacionados